<DOC>
	<DOCNO>NCT01160120</DOCNO>
	<brief_summary>The purpose study determine mid level tenofovir , lamivudine , efavirenz , 144 week safety efficacy generic fix dose combination tenofovir /lamivudine/efavirenz tablets 300/300/600 mg Thai HIV-infected patient .</brief_summary>
	<brief_title>Therapeutic Drug Monitoring ( TDM ) Generic Tenofovir/Lamivudine/Efavirenz</brief_title>
	<detailed_description>The trial drug FDC TDF/3TC/EFV new formulation combine fix dos nucleoside reverse transcriptase inhibitor lamivudine 300 mg tenofovir disoproxil fumarate 300 mg non nucleoside reverse transcriptase inhibitor efavirenz 600 mg daily one-tablet HAART . Co-formulated TDF/3TC/EFV demonstrate bioequivalent original individual EFV 3TC TDF Indian healthy volunteer ( unpublished data ) . It evaluate clinical trial .</detailed_description>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Signed informed consent Evidence HIV infection Age &gt; 18 year On TDF/3TC/EFV ( separated pill ) contain HAART regimen VL &lt; 50 copy within 24 week ARV na√Øve eGFR &gt; 70 cc/min Currently AIDS define illness No history NRTI/NNRTI/PI failure Willing adhere protocol requirement Any history taking CYP450 inhibitor inducer drug within 14 day enrollment study Current pregnancy lactate plan pregnant Active opportunistic infection ALT 2 x upper limit Creatinine 1.5 time upper limit Active drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>fix dose combination</keyword>
	<keyword>tenofovir</keyword>
	<keyword>lamivudine</keyword>
	<keyword>efavirenz</keyword>
	<keyword>therapeutic drug level</keyword>
	<keyword>safety efficacy</keyword>
	<keyword>HIV</keyword>
	<keyword>To evaluation new formulation FDC TDF/3TC/EFV</keyword>
</DOC>